#NanoString Technologies

[janetushar1]

Cancer Profiling Market to Hit $19.28 Billion by 2032

The global Cancer Profiling Market was valued at USD 9.4 Billion in 2024 and it is estimated to garner USD 19.28 Billion by 2032 with a registered CAGR of 10.8% during the forecast period 2024 to 2032.

The report throws light on the competitive scenario of the global Cancer Profiling Market to know the competition at global levels. Market experts also provided the outline of each leading player of the global Cancer Profiling Market for the market, considering the key aspects such as the areas of operation, production, and product portfolio. In addition, the companies in the report are studied based on vital factors such as company size, market share, market growth, revenue, production volume, and profit.

The global Cancer Profiling Market is fragmented with various key players. Some of the key players identified across the value chain of the global Cancer Profiling Market include Illumina Inc. (U.S.), QIAGEN (Germany), NeoGenomics Laboratories Inc. (U.S.), HTG Molecular Diagnostics Inc. (U.S.), Genomic Health Inc. (U.S.), Caris Life Sciences (U.S.), Helomics Corporation (U.S.), NanoString Technologies Inc. (U.S.), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (U.S.) etc. Considering the increasing demand from global markets various new entries are expected in the Cancer Profiling Market at regional as well as global levels.

Download Cancer Profiling Market Sample Report PDF: https://www.vantagemarketresearch.com/cancer-profiling-market-2101/request-sample

Top Competitors:

Illumina Inc. (U.S.), QIAGEN (Germany), NeoGenomics Laboratories Inc. (U.S.), HTG Molecular Diagnostics Inc. (U.S.), Genomic Health Inc. (U.S.), Caris Life Sciences (U.S.), Helomics Corporation (U.S.), NanoString Technologies Inc. (U.S.), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (U.S.)

Understanding the Industry's Growth, has released an Updated report on the Cancer Profiling Market. The report is mixed with crucial market insights that will support the clients to make the right business decisions. This research will help new players in the global Cancer Profiling Market to sort out and study market needs, market size, and competition. The report provides information on the supply and market situation, the competitive situation and the challenges to the market growth, the market opportunities, and the threats faced by the major players.

Regional Analysis

-North America [United States, Canada, Mexico]

-South America [Brazil, Argentina, Columbia, Chile, Peru]

-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

-Middle East & Africa [GCC, North Africa, South Africa]

-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

You Can Buy This Report From Here: https://www.vantagemarketresearch.com/buy-now/cancer-profiling-market-2101/0

Full Analysis Of The Cancer Profiling Market:

Key findings and recommendations point to vital progressive industry trends in the global Cancer Profiling Market, empowering players to improve effective long-term policies.

The report makes a full analysis of the factors driving the development of the market.

Analyzing the market opportunities for stakeholders by categorizing the high-growth divisions of the market.

Questions answered in the report

-Who are the top five players in the global Cancer Profiling Market?

-How will the global Cancer Profiling Market change in the next five years?

-Which product and application will take the lion's share of the global Cancer Profiling Market?

-What are the drivers and restraints of the global Cancer Profiling Market?

-Which regional market will show the highest growth?

-What will be the CAGR and size of the global Cancer Profiling Market during the forecast period?

Read Full Research Report with [TOC] @ https://www.vantagemarketresearch.com/industry-report/cancer-profiling-market-2101

Reasons to Purchase this Cancer Profiling Market Report:

-Analysis of the market outlook on current trends and SWOT analysis.

-The geographic and country level is designed to integrate the supply and demand organizations that drive industry growth.

-Cancer Profiling Industry dynamics along with market growth opportunities in the coming years.

-Cancer Profiling Market value (million USD) and volume (million units) data for each segment and sub-segment.

1 year consulting for analysts along with development data support in Excel. Competitive landscape including market share of major players along with various projects and strategies adopted by players in the last five years.

Market segmentation analysis including qualitative and quantitative analysis including the impact on financial and non-economic aspects.

Complete company profiles that include performance presentations, key financial overviews, current developments, SWOT analyzes and strategies used by major Cancer Profiling Market players.

Check Out More Reports

Global Single-Use Bioprocessing Market:  Report Forecast by 2032

Global Medical Device Security Market: Report Forecast by 2032

Global Fitness Tracker Market: Report Forecast by 2032

Global Alternative Lending Platform Market: Report Forecast by 2032

Global Animal Feed Additives Market: Report Forecast by 2032

[leedsomics]

UCS: a unified approach to cell segmentation for subcellular spatial transcriptomics

Subcellular Spatial Transcriptomics (SST) represents an innovative technology enabling researchers to investigate gene expression at the subcellular level within tissues. To comprehend the spatial architecture of a given tissue, cell segmentation plays a crucial role in attributing the measured transcripts to individual cells. However, existing cell segmentation methods for SST datasets still face challenges in accurately distinguishing cell boundaries due to the varying characteristics of SST technologies. In this study, we propose a unified approach to cell segmentation (UCS) specifically designed for SST data obtained from diverse platforms, including 10X Xenium, NanoString CosMx, MERSCOPE, and Stereo-seq. UCS leverages deep learning techniques to achieve high accuracy in cell segmentation by integrating nuclei segmentation from nuclei staining and transcript data. Compared to current methods, UCS not only provides more precise transcript assignment to individual cells but also offers computational advantages for large-scale SST data analysis. The analysis output of UCS further supports versatile downstream analyses, such as subcellular gene classification and missing cell detection. By employing UCS, researchers gain the ability to characterize gene expression patterns at both the cellular and subcellular levels, leading to a deeper understanding of tissue architecture and function. http://dlvr.it/T9M8Cl

[ramtracking]

Bruker to Acquire NanoString with $392.6M Winning Bid [ Bruker ]

Bruker to Acquire NanoString with $392.6M Winning Bid [News Summary] NanoString Technologies has found a buyer in Bruker, which will acquire substantially all the bankrupt company’s assets for approximately… NanoString Technologies, Inc. (“NanoString” or “the Company”), a leading provider of life science tools for discovery and translational… Bruker has emerged as the winner of an auction for…

[robjackson616-blog]

Precision Medicine  Market to Witness Unbelievable Growth from 2024 to 2030:

According to HTF Market Intelligence, theGlobal Precision Medicine market to witness a CAGR of 12% during forecast period of 2024-2030. Global Precision Medicine Market Breakdown by Application (Diagnostics, Therapeutics, Pharmaceuticals, Medical Devices, Others) by Type (Consumables, Instruments, Services, Others) by Technology (Bioinformatics, Big Data Analytics, Drug Discovery, Gene Sequencing, Companion Diagnostics, Others) and by Geography (North America, South America, Europe, Asia Pacific, MEA). The Precision Medicine market size is estimated to increase by USD xx Services at a CAGR of 12% from 2024 to 2030.. Currently, market value is pegged at USD  Services.

Get Detailed TOC and Overview of Report @

Precision Medicine is an innovative approach to medical treatment and healthcare that takes into account individual differences in patients' genes, environments, and lifestyles. It involves tailoring medical decisions, practices, interventions, and therapies to the characteristics of an individual patient, rather than adopting a one-size-fits-all approach.

Some of the key players profiled in the study are Biocrates Life Sciences AG (Austria), Nanostring Technologies (United States), Intomics (Denmark), Pfizer Inc. (united States), Eagle Genomics Ltd (United Kingdom), Teva Pharmaceuticals (Israel), Laboratory Corporation of America Holdings (United States), Novartis AG (Switzerland), Qiagen NV (Netherlands).

Book Latest Edition of Global Precision Medicine Market Study @ https://www.htfmarketintelligence.com/buy-now?format=1&report=1309

About Us:

HTF Market Intelligence is a leading market research company providing end-to-end syndicated and custom market reports, consulting services, and insightful information across the globe. HTF MI integrates History, Trends, and Forecasts to identify the highest value opportunities, cope with the most critical business challenges and transform the businesses. Analysts at HTF MI focuses on comprehending the unique needs of each client to deliver insights that are most suited to his particular requirements.

Contact Us:

Craig Francis (PR & Marketing Manager) HTF Market Intelligence Consulting Private Limited Phone: +15075562445 sales@htfmarketintelligence.com

[creative-news-alert]

Phosphor Screen Scanner Market is Estimated to Witness High Growth Owing to Increasing Adoption in Radiology and Molecular Diagnostics.

The phosphor screen scanner market consists of medical imaging devices that digitize phosphor screen plates used in radiology and dental applications. Phosphor screens are used in X-ray imaging and store X-ray data as a latent image. Phosphor screen scanners scan these plates and convert the stored X-ray information into a digital format such as DICOM that can be viewed and processed on computers. The devices find widespread application in general radiography, mammography, orthopedic imaging, and dental applications. The global phosphor screen scanner market is estimated to be valued at US$ 288 Bn in 2023 and is expected to exhibit a CAGR of 10.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: One of the major drivers for the growth of the phosphor screen scanner market is the increasing adoption of digital radiology and molecular diagnostics. Digital radiography replaces conventional X-ray film with phosphor screen plates and scanners, offering advantages such as improved image quality, reduced X-ray dosage, and instant image availability. It is widely being adopted across hospitals and diagnostic centers. Furthermore, the rising incidence of chronic diseases such as cancer is leading to increasing diagnostic imaging procedures. This in turn is promoting the demand for phosphor screen scanners in conjunction with X-ray imaging equipment. In addition, technological advancements resulting in more sensitive phosphor screens and high-resolution scanners are further supporting the market growth over the forecast period. SWOT Analysis Strength: The phosphor screen scanner market size has strong growth potential owing to rising demand for digital radiography systems. Phosphor screen scanners offer high-resolution images and are less expensive than traditional systems. They are also portable and allow for quick scanning of images. Weakness: Phosphor screen scanners have some limitations compared to newer digital options. They require specialized phosphor plates and chemicals for developing images. The plates also have a limited useful lifetime and need replacement. Phosphor screen scanners also cannot perform real-time imaging. Opportunity: Growth opportunities exist in emerging markets as healthcare infrastructure improves. Asian countries are expected to see higher adoption rates for phosphor screen scanners. Enhanced models with better image quality and portability also provide room for innovation. Integrating artificial intelligence could help automate image analysis. Threats: Stiff competition exists from newer digital radiography technologies like CR and DR systems. These offer advantages like real-time imaging, lower operating costs, and wider applications. Strict regulations around healthcare technologies also pose compliance challenges. Rising environmental concerns around disposal of phosphor plates act as a restraint. Key Takeaways The global phosphor screen scanner market is expected to witness high growth over the forecast period driven by widespread applications in hospitals, clinics and diagnostic centers.

Regional analysis: The Asia Pacific region holds the leading share of the global phosphor screen scanner market currently. China dominates the APAC market owing to its large population and healthcare sector expansion programs. India is another highly lucrative market and is expected to see a double digit CAGR through 2031. This can be attributed to growing government focus on universal healthcare and increasing investments in medical infrastructure development projects. Key players: Key players operating in the phosphor screen scanner market are Intomics, GENinCode, NanoString, Tepnel Pharma Services Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc, QIAGEN, Quest Diagnostics Incorporated, Medtronic, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, bioMérieux SA, F. Hoffmann-La Roche Ltd, Eli Lilly & Company, GlaxoSmithKline plc, Cepheid, AstraZeneca PLC, Myriad Genetics, Inc., Bristol-Myers Squibb Company, and Foundation Medicine, Inc. These companies are focusing on product launches and partnerships to strengthen their positions.Get more insights on this topic:https://www.newswirestats.com/phosphor-screen-scanner-market-size-and-outlook/

[omkarpatel]

Spatial Genomics Transcriptomics is Estimated to Witness High Growth Owing to Opportunity of Healthcare Advancements

Spatial genomics transcriptomics is an emerging technique which allows simultaneous analysis of RNA expression levels within individual cells in their original tissue context at high resolution. It enables unbiased mapping of the cellular composition of tissues and detecting cell types, states and interactions in situ. The technique combines spatial imaging with sequencing to determine where transcripts are located in fixed and stained tissues. This provides immense advantages over other bulk tissue RNA-seq techniques as it offers spatial context and cellular resolution of gene expression.

The global Spatial Genomics Transcriptomics Market s estimated to be valued at US$ 450 million in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The key opportunity driving the high growth of the spatial genomics transcriptomics market is its potential to advance healthcare. Spatial genomics can unravel the complex interplay between cells in healthy and diseased tissues. This technique is being applied to further understand various disease conditions like cancer at an unprecedented scale and resolution. Researchers are mapping expression of genes in tissues to gain novel insights into development and progression of diseases. Spatial understanding of genetic changes in situ can prove pivotal in discovering biomarkers and designing more precise therapies. Several biopharma companies are investing heavily in spatial genomics to accelerate drug discovery and development efforts. The ability of this technique to provide precise spatial mapping of gene expression holds immense potential to transform healthcare in the coming years. Porter’s Analysis Threat of new entrants: The spatial genomics transcriptomics market requires high capital investment and established distribution channels which poses significant barriers for new players. Bargaining power of buyers: Large pharmaceutical companies have strong bargaining power due to their high volume purchases. However, various product options provide flexibility to buyers. Bargaining power of suppliers: Key technology providers like 10x Genomics have considerable influence over prices and innovations. Nonetheless, their dependence on a small buyer base mitigates bargaining power. Threat of new substitutes: Limited substitutes exist for spatial genomics transcriptomics techniques due to their unique capability to detect molecular profiles of tissues at high resolution. Competitive rivalry: Players like NanoString and Illumina compete intensely on technology advancements, licensing deals and geographic expansions. SWOT Analysis Strength: Spatial genomics transcriptomics provides comprehensive single-cell analysis without requiring cell dissociation. It allows mapping gene expression in anatomical context of tissues. Weakness: High costs, complex workflow and heavy data analysis requirements restrict wider adoption. Challenges remain in achieving optimal resolution, scale and specificity. Opportunity: Growing R&D in genomics, drug discovery and development is stimulating demand. Potential clinical applications include cancer diagnostics, neuroscience and inflammatory diseases. Threats: Stringent regulatory norms and data privacy laws pose compliance issues. Slow commercialization compared to other omics technologies. Key Takeaways The global spatial genomics transcriptomics market is expected to witness high growth. Advancing capabilities to reveal cell-type organization and gene correlations at microanatomical scales will support market rise. The global Spatial Genomics Transcriptomics Market is estimated to be valued at US$ 300 million in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023-2030. North America dominates current demand owing to extensive research and technology development activities in the region. Asia Pacific is likely to be the fastest growing market for spatial genomics transcriptomics during the forecast period. Countries like China, India and South Korea are strengthening genomic research infrastructure which will support technology adoption. Key players: Key players operating in the spatial genomics transcriptomics market are 10x Genomics, NanoString Technologies, Seven Bridges Genomics, Dovetail Genomics, S2 Genomics and others. 10x Genomics has established itself as the market leader by launching product upgrades frequently and filing patents for new techniques.

[blog-site-for-market-research]

Cancer Diagnostics Market Size, Industry Trends and Forecast to 2032

Market Overview

The Cancer Diagnostics Market Size was assessed at USD 160.2 billion in 2021 and is expected to rise from USD 170.9 billion in 2022 to USD 269.1 billion by 2030, with a compound yearly growth rate (CAGR) of 6.70% during the forecast period (2022- 2030). We will provide COVID-19 impact analysis with the report, along with all the extensive key developments in the market post the coronavirus disease outbreak.

Top Boosters and Barriers

Cancer remains of the most common reasons for deaths worldwide and the alarming rate at which it is gaining prevalence is one of the factors that boost the market demand. Given the aggravating situation, healthcare specialists are increasing their focus on developing advanced diagnostic solutions to analyze the prevalence level. Early detection helps increase the treatment’s success rate and therefore, healthcare vendors and the top players armed with awareness campaigns, are busy conducting routine checkups. Other favorable factors can be the rising incidences of oncologic disorders, frequent technological innovations in diagnostics, and the soaring demand for accurate screening tests.

Technological innovations in several fields including imaging, biomarkers, endoscopy; biopsy, and the rapidly expanding geriatric population also work in the cancer diagnostics market’s favor. Rising number of initiatives by the government bodies and the increasing funds being allocated in this field also fosters market growth. But, the significant capital investment required combined with the shortage of skilled medical professionals could deter the market growth in the following years. Having said that, developing healthcare infrastructure across emerging nations and the escalating preference for companion diagnostics offer a host of attractive opportunities to the leading market contenders.

Many of the top firms in the global market are able to sustain their positions by adopting strategies such as product innovations and rigorous R&D efforts for the introduction of the same. It is expected that the competition in the worldwide market could intensify substantially over the next few years, as several vendors are now more focused on carrying out researches and coming up with innovative diagnostic techniques via product range expansions, acquisitions, collaborations and mergers. To illustrate, in November 2020, NanoString Technologies collaborated with the Oregon Health & Science University for the development of GeoMx Digital Spatial Profiler-based protein assays that cater to patients with breast cancer. This product innovation is expected to boost the application range of spatial biology, with the bigger picture being improved patient care via modern molecular testing.

Market Segmentation

Cancer diagnostics industry can be categorized depending on type, application and end user.

The types of cancer diagnostics trend in the market are biomarkers testing, imaging testing, biopsy, in vitro diagnostic testing, and more. Imaging testing types such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scan are non-invasive, pain-free and quick diagnostic solutions and therefore, observe significant demand in the healthcare industry.

Some of the top market applications are breast cancer, lung cancer, melanoma cancer, colorectal cancer, liver cancer, prostate cancer, and others.

Research institutes, hospitals and clinics, diagnostic centers, and others are the key market end-users.

Regional Insight

Asia Pacific or APAC, the Americas, Middle East & Africa or MEA and Europe are the primary markets for cancer diagnostics.

America is currently leading the global market for cancer diagnostics, thanks to the burgeoning elderly population and the high healthcare spending. The well-developed healthcare industry also favors the American market, especially in the United States. The emergence of the latest flow cytometry reagents in terms of diagnostics, growth in government-led initiatives to spread awareness regarding cancer and the strong support of the USFDA with regard to biomarker development are a few other major growth rendering factors in the regional market.

Since 2018, Europe has remained the second biggest market for cancer diagnostics, as a result of the mounting awareness level among people about cancer and the surge in technological advances in the oncology field. The escalating need for advanced diagnostics for the disease also makes Europe a market to watch out for in the coming years. Germany is the frontrunner in the regional market for cancer diagnostics, considering that the country has a massive patient pool and accommodates a huge population of highly skilled healthcare professionals.

APAC could record the highest growth rate in the ensuing years, given that the region holds a vast cancer-afflicted population and this has bolstered the need for more effective diagnostics. This situation is also favored by the constant support of the government that is taking initiatives to improve the healthcare industry in the region. Fast developing economies like India, Japan and China with their thriving manufacturing industries and cheaper production costs, are sparking the interest of several international players that desire to establish their production units in the region.

Top Industry Contenders

Top industry contenders analyzed in the MRFR report include Biotheranostics, Illumina, Inc., Exact Sciences Corporation, QIAGEN N.V., Arquer Diagnostics Ltd, Abbott Laboratories, Inc., Thermo Fisher Scientific, Inc., Roche Diagnostics, Siemens Healthcare, GE Healthcare, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), Koninklijke Philips N.V., Inc., BioMark Diagnostics Inc., Cancer Diagnostics, Inc., to name a few.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com

[cavenewstimes]

NanoString Says Disagrees With Jury's Patent-Infringement Verdict; Withdraws Outlook

(RTTNews) – NanoString Technologies Inc. (NSTG) stated it respectfully disagreed with the decision of the jury in the U.S. District Court for the District of Delaware. The business will look for to have the decision reversed or changed in post-trial movements and after that anticipates to attract the U.S. Court of Appeals for the Federal Circuit, a court that focuses on patent conflicts. On 17th…

[fmarkets]

Nanostring Technologies Inc Achieves Impressive Revenue Growth, Driving Reduction in Losses during Q3 20232. https://csimarket.com/stocks/news.php?code=NSTG&date=2023-11-07123536&utm_source=dlvr.it&utm_medium=tumblr

[poonamcmi]

Global Biopharmaceutical and Biomedicine Market Is Estimated To Witness High Growth Owing To Increasing Use of Biological Products

The global Biopharmaceutical and Biomedicine Market is estimated to be valued at US$ 561,375.9 million in 2022 and is expected to exhibit a CAGR of 9.6% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: Biopharmaceutical and biomedicine products are drugs derived from biological sources, including living organisms, cells, and proteins. These products are used to treat various diseases and medical conditions. The market for biopharmaceutical and biomedicine products is driven by the increasing use of biological therapies, which offer numerous advantages over traditional pharmaceuticals, such as targeted treatment, reduced side effects, and enhanced efficacy. B) Market Key Trends: One key trend in the biopharmaceutical and biomedicine market is the growing importance of personalized medicine. Advances in genomics and biotechnology have made it possible to tailor treatment plans to individual patients based on their genetic makeup. This approach allows for more precise and effective treatment, leading to better patient outcomes. For example, the use of monoclonal antibodies in cancer treatment has shown promising results in targeting specific cancer cells and improving survival rates. C) PEST Analysis: Political: Government regulations play a crucial role in the biopharmaceutical and biomedicine industry. Stringent regulations ensure the safety and efficacy of these products, but they can also increase the time and cost associated with development and approval processes. Economic: The demand for biopharmaceutical and biomedicine products is influenced by economic factors such as healthcare expenditure, insurance coverage, and reimbursement policies. Social: The increasing prevalence of chronic diseases and the aging population are driving the demand for biopharmaceutical and biomedicine products. Additionally, patient preferences for targeted and personalized therapies are shaping market trends. Technological: Advances in biotechnology and genomics have revolutionized the field of biopharmaceuticals, enabling the development of innovative products and therapies. D) Key Takeaways: - The global Biopharmaceutical And Biomedicine Market Growth is expected to witness high growth, exhibiting a CAGR of 9.6% over the forecast period. This growth can be attributed to the increasing use of biological products and advancements in personalized medicine. - North America is anticipated to dominate the market, driven by factors such as a well-established healthcare infrastructure, high healthcare expenditure, and favorable regulations. - Key players operating in the global biopharmaceutical and biomedicine market include Amgen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Pfizer Inc., Sanofi, Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol-Myers Squibb Company, NanoString, QIAGEN, Affimed GmbH, GSK plc., Merck KgaA, and Teva Pharmaceutical Industries Ltd. In conclusion, the global biopharmaceutical and biomedicine market is poised for substantial growth due to the increasing use of biological products and the rise in personalized medicine. The market is heavily influenced by political, economic, social, and technological factors. North America is expected to be the fastest-growing and dominating region in this market. Key players in this industry are focused on developing innovative products and therapies to cater to the growing demand for advanced treatments.

[yashvicmi01]

Global Lung Cancer Diagnostic and Screening Market Is Estimated To Witness High Growth Owing To Rising Awareness and Technological Advancements

The global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$ 1,931.0 Mn in 2021 and is expected to exhibit a CAGR of 7.8% over the forecast period 2021-2028, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: Lung cancer diagnostic and screening are crucial in the early detection and treatment of lung cancer. Diagnostic tests such as imaging, biomarker tests, and genetic tests help in the accurate diagnosis of lung cancer. Screening tests such as low-dose computed tomography (LDCT) are used to detect lung cancer in individuals with high-risk factors. These tests play a significant role in improving patient outcomes by enabling early detection and effective treatment. B) Market Dynamics: The two key drivers contributing to the growth of the lung cancer diagnostic and screening market are: 1. Rising Awareness: With the increasing prevalence of lung cancer worldwide, there has been a significant rise in awareness about the importance of early detection and screening. Government initiatives, awareness campaigns, and educational programs have played a crucial role in disseminating information about the risk factors, symptoms, and available diagnostic and screening options for lung cancer. 2. Technological Advancements: Advancements in medical imaging technology, genomics, and molecular biology have revolutionized lung cancer diagnostics and screening. The development of non-invasive biomarker tests, liquid biopsies, and next-generation sequencing techniques has improved the accuracy and efficiency of lung cancer detection. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms in the interpretation of medical images has enhanced diagnostic precision. C) Segment Analysis: One segment dominating the global lung cancer diagnostic and screening market is genetic tests. Genetic tests play a crucial role in identifying specific gene mutations or alterations that are associated with lung cancer. These tests help in determining the appropriate treatment options and predicting treatment response. The increasing demand for personalized medicine and targeted therapies has propelled the growth of the genetic tests segment. D) PEST Analysis: Political: Government initiatives, regulations, and reimbursement policies influence the adoption of lung cancer diagnostic and screening methods. Economic: The economic factors such as healthcare expenditure, insurance coverage, and affordability impact the accessibility of diagnostic and screening services. Social: Increasing awareness, changing lifestyles, and smoking habits influence the demand for lung cancer diagnostic and screening. Technological: Advancements in medical imaging technology, genomics, and molecular biology have improved the accuracy and efficiency of lung cancer diagnostic and screening methods. E) Key Takeaways: - The global Lung Cancer Diagnostic and Screening Market is expected to witness high growth, exhibiting a CAGR of 7.8% over the forecast period, due to increasing awareness about the importance of early detection and screening and advancements in technology. - Among the regional analysis, North America is the fastest-growing and dominating region in the lung cancer diagnostic and screening market, attributed to the high prevalence of lung cancer, well-established healthcare infrastructure, and favorable reimbursement policies. - Key players operating in the global lung cancer diagnostic and screening market include Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. These companies are focused on research and development activities, strategic collaborations, and mergers and acquisitions to strengthen their market position and introduce innovative diagnostic and screening solutions.

[rohans18]

Tumor Tracking Systems Market Research Report, Growth, Analysis and Forecast 2028

Global Tumor Tracking Systems Market, By Device Type (Direct Tumor Tracking Systems, Respiratory Tracking Systems, Others), Application (Prostate Cancer, Lung Cancer, Breast Cancer, Others), End-User (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centres, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028.

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Tumor Tracking Systems marketing report. The report has a lot to offer to both established and new players in the Tumor Tracking Systems industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Tumor Tracking Systems market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

The major players covered in the tumor tracking systems market report are Illumina, Inc., QIAGEN, NeoGenomics Laboratories, Inc., HTG Molecular Diagnostics, Caris Life Sciences, Genomic Health, Helomics Corp, NanoString, Sysmex Corporation, Guardant Health, FOUNDATION MEDICINE, INC, F. Hoffmann-La Roche Ltd, GenScript, Tempus, Boreal Genomics, Inc., Perthera, Inc., Agendia, OmniSeq Corporation and HistoGeneX NV among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-tumor-tracking-systems-market

With the help of credible Tumor Tracking Systems market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Tumor Tracking Systems market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Tumor Tracking Systems Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[mrunalnerkarblog]

The Global Kidney Cancer Drugs Market Is Witnessing High Growth Owing To the Increasing Prevalence of Kidney Cancer Cases in the World

Market Overview:

Kidney cancer is a serious medical condition. There are several types of the disease, including medullary and sarcoma, which are less common but highly aggressive. They develop in the soft tissue surrounding the kidney, as well as in the fat that surrounds it. Surgical removal of the affected organ is the standard treatment for this type of cancer. However, if the disease has spread to other organs or spreads beyond the kidney, chemotherapy or systemic therapy may be needed. A biopsy is another test for kidney cancer. It involves inserting a thin needle into a tumor and looking through the tissue under a microscope to detect cancer cells. Biopsies aren't always accurate, and the healthcare provider may not recommend them. If the tumor has spread to lymph nodes or is large, a biopsy may be performed. This will allow the doctor to evaluate the tumor's location and the extent of its spread and determine its stage and aggressiveness.

Competitive Landscape:

Major players operating in the global kidney cancer drugs market include Quest Diagnostics Incorporated, Illumina Inc, Rosetta Genomics, Sysmex Corporation, NanoString Technologies Inc, NeoGenomics Laboratories, Myriad Genetics Inc, Argos Therapeutics, Prometheus Laboratories, Immatics Biotechnologies, Aveo Pharmaceuticals, Abbott Laboratories, Onyx, Cipla Limited, Roche, Eisai, Bristol-Myers Squibb, Thermo Fisher Scientific Inc, Amgen, Active Biotech, GlaxoSmithKline Plc, Genentech Inc., F. Hoffmann-La Roche Ag, Exelixis Inc, Novartis International AG, Pfizer Inc., and Bayer AG.

Key Market Drivers:

The increasing incidence of kidney cancer cases in the world is expected to augment the growth of the global kidney cancer drugs market. For instance, according to Cancer.Net, in 2020, around 431,288 individuals in the world were suffering from kidney cancer. Targeted drug therapy uses drugs or substances to attack the cancer cells in a specific area of the body. This can reduce side effects caused by the drugs while still killing the cancer cells. Anti-angiogenic agents block the growth of the blood vessels feeding the tumor. A multikinase inhibitor can stop the growth of cancer cells, while a tyrosine kinase inhibitor works by blocking an enzyme that helps the cancer cells grow. Increasing treatment launches by key players are estimated to enhance the growth of the global kidney cancer drugs market.  

Covid-19 Impact Analysis

During the COVID-19 pandemic, the increasing focus on the virus-infected cases affected the growth of the global kidney cancer drugs market.  Moreover, sudden stress on the healthcare sector also impacted the market growth.

Key Takeaways

·         North America is expected to dominate the growth of the global kidney cancer drugs market, owing to the increasing prevalence of kidney cancer cases in the region. For instance, according to Cancer.Net, in 2020 around 79,000 adults in the U.S. were diagnosed with kidney cancer.

·         The Asia Pacific is estimated to witness high growth in the global kidney cancer drugs market, owing to the increasing expansion of cancer hospitals in the region. For instance, according to the Indian Cancer Society, India has around 27 dedicated cancer hospitals currently.

[sueheaven]

Precision Medicine market Is Likely to Experience a Tremendous Growth in Near Future

Latest business intelligence report released on Global Precision Medicine Market, covers different industry elements and growth inclinations that helps in predicting market forecast. The report allows complete assessment of current and future scenario scaling top to bottom investigation about the market size, % share of key and emerging segment, major development, and technological advancements. Also, the statistical survey elaborates detailed commentary on changing market dynamics that includes market growth drivers, roadblocks and challenges, future opportunities, and influencing trends to better understand Precision Medicine market outlook. List of Key Players Profiled in the study includes market overview, business strategies, financials, Development activities, Market Share and SWOT analysis are:

Biocrates Life Sciences AG (Austria)

Nanostring Technologies (United States)

Intomics (Denmark)

Pfizer Inc. (united States)

Eagle Genomics Ltd (United Kingdom)

Teva Pharmaceuticals (Israel)

Laboratory Corporation of America Holdings (United States)

Novartis AG (Switzerland)

Qiagen NV (Netherlands)

Quest Diagnostics Incorporated (United States)

 F. Hoffmann-La Roche AG (Switzerland)

Precision Medicine is refer to customization of medical treatment by genetic understanding of the patients. It is use to analyze cause of disease at molecular level. New technologies in precision medicine market like genome sequencing, targeted sequencing and continuous research and development owing to increasing number of cancer and rare diseases growing the market. In addition development in personalized treatment, cost- effective therapies are projected to drive the sales potentially over forecast period. Key Market Trends: Growing cost-effective genomic and molecular biology testing techniques Opportunities: Growing Research in Big Pharma and Biotech Companies Market Growth Drivers: Growing incidence of cancer and rare diseases

Increasing Use of Big Data in Healthcare

Rising Demand of Personalized Treatment 

Challenges: Intense Competition among the vendors The Global Precision Medicine Market segments and Market Data Break Down by Type (Consumables, Instruments, Services, Others), Application (Diagnostics, Therapeutics, Pharmaceuticals, Medical Devices, Others), End User (Diagnostic Tool companies, Pharma & Biotech Companies, Clinical Laboratories, Healthcare, IT/Big Data Companies), Technology (Genomics, Transcriptomics, Epigenomics), Sequencing (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, Chain Termination Sequencing, Nanopore Sequencing)

Presented By

AMA Research & Media LLP

[chemicaltech]

immune-oncology assay  Market worth USD 14.1 billion by 2031

The global immune-oncology assay market was valued at USD 4.2 billion in 2021 and it is anticipated to grow further up to USD 14.1 billion by 2031, at a CAGR of 12.9% during the forecast period.

One kind of immunoassay that is mostly used to diagnose cancer is the immuno-oncology assay. It is a process that profiles different analytes by simultaneously detecting and measuring them, including proteins, biomolecules, growth factors, cytokines, and chemokines. This method primarily targets and eliminates cancer cells using the body’s natural defensive mechanism. This assay is used for in vitro research to investigate the complex tumor microenvironment, the dynamic interactions between cancer cells and immune cells, and the perception of immunoreactivity in a variety of cell-based assays to determine the mode of action.

Get Sample Here – https://www.globalinsightservices.com/request-sample/GIS10299

Major Players in the Global Immuno-Oncology Assay Market

The key players studied in the market are Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Illumina, Inc. (US), NanoString Technologies, Inc. (US), Sartorius AG (Germany), HTG Molecular Diagnostics, Inc. (US), QIAGEN N.V. (Netherlands), Merck Millipore (US), PerkinElmer, Inc. (US), Abbott Laboratories, Inc. (US), Guardant Health, Inc. (US), and bioMérieux SA (France) among others.

Global Immuno-Oncology Assay Market

By Product & Services

  Consumables

Instruments

Software & Services

By Technology

  PCR

Immunoassay

NGS

ISH

Flow Cytometry

  Market Trends and Drivers

As a multi-stage carcinogenesis process involving numerous molecular pathway events, cancer is a complex illness that arises. So, the diagnosis, prognosis, and treatment of cancer are all accompanied with a number of challenges. In this aspect, a single marker is not useful due to the complexity of cancer. Each cancer also differs from other cancer kinds in terms of its molecular profile. As a result, the use of immuno-oncology assays has proved crucial for comprehending cancer signatures and creating individualized treatments. Over the past few years, cancer has become more commonplace across the globe. In 2018, there were 9.6 million fatalities due to cancer, which has overtaken all other causes of mortality in the world. GLOBOCAN predicts that by 2040, there would be over 30 million new instances of cancer, up from 18 million in 2018. Africa, Asia, Central and South America account for more than 60% of all new cancer cases, and these regions also account for 70% of all cancer-related fatalities worldwide. As a result, there is a need for considerable research to be done for cancer detection and therapy, and immuno-oncology assays play a significant role in this study.

  With Global Insight Services, you receive:

·         10-year forecast to help you make strategic decisions

·         In-depth segmentation which can be customized as per your requirements

·         Free consultation with lead analyst of the report

·         Excel data pack included with all report purchases

·         Robust and transparent research methodology

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm

headquartered in Delaware, US. We are committed to providing our clients

with highest quality data, analysis, and tools to meet all their market research

needs. With GIS, you can be assured of the quality of the deliverables, robust

and transparent research methodology, and superior service.

  Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1-833-761-1700

[cool-akashy-maximize]

lung Cancer Screening Market Growth Opportunities, Market Shares, Future Estimations and Key Countries by 2029

lung Cancer Screening Market: size was valued at USD 2.18 Billion in 2021 and the total Lung Cancer Screening revenue is expected to grow at a CAGR of 8.32% from 2022 to 2029, reaching nearly USD 4.13 Billion.

lung Cancer Screening Market Overview:

The lung Cancer Screening Market study gives a comprehensive view of the competition, including the market share and company profiles of the major global competitors. The scope of the research includes a full examination of the lung Cancer Screening Market, as well as the reasons for variations in the industry's growth between regions.

lung Cancer Screening Market Dynamic:

An increased focus on research and development activities of lung cancer diagnostic and screening tests is one of the major factors driving the lung cancer screening market growth. For example, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) developed a nanoparticle-based method for early lung cancer detection via a simple urine test. The method identifies biomarkers produced by peptide-coated nanoparticles interacting with disease-associated proteases in the tumor microenvironment. Experiments in two distinct lung cancer mouse models revealed that the urine test may identify tumors as tiny as 2.8 mm. The researchers expect that this noninvasive diagnosis approach would lower the number of false positives associated with a current test method and allow them to discover more cancers in the early stages of illness.

Order A Free Sample PDF @ https://www.maximizemarketresearch.com/request-sample/166924

Market Scope:

Following the completion of market engineering, which included market statistics computations, market size estimations, market forecasts, market breakdown, and data triangulation, extensive primary research was done to gather information and verify and validate important numbers. To undertake market estimating and forecasting for the overall market segments and sub-segments described in this research, top-down and bottom-up tactics, as well as different data triangulation procedures, were often employed throughout the market engineering process. Extensive qualitative and quantitative analysis is performed on all data obtained during the market engineering process in order to provide essential information throughout the report.

lung Cancer Screening Market Segmentation:

Based on Cancer Type, the Non-small Cell Lung Cancer (NSCLC) segment dominated the global lung cancer screening market with the highest market share of 78% in 2021. This segment is further expected to maintain its dominance with the highest market share of 85% at the end of the forecast period. Non-small cell lung cancer (NSCLC) is the most common type of cancer, accounting for 85% of lung cancer occurrences. However, NSCLC subtypes include large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other less common types of NSCLC. Increased screening awareness in developed and developing countries, along with an increase in NSCLC incidence globally, is expected to drive segment growth over the forecast period. As a result, during the forecast period, the segment is expected to grow at an 8.24% CAGR. According to the American Cancer Society, approximately 84% of all lung malignancies are non-small cell, while 13% are SCLC. Meanwhile, according to Cancer.Net, the five-year survival rate for NSCLC is 24%, compared to 6% for SCLC.

lung Cancer Screening Market Key Players:

• GE Healthcare (United States) • PenRad Technologies, Inc. (United States) • NanoString, Myriad Genetics Inc. (United States) • OncoCyte (United States) • Biodesix (United States) • Broncus (United States) • Abbott (United States) • Illumina, Inc., (United States) • Thermo Fischer Scientific (United States) • Medtronic (United States) • Nuance Communications, Inc. (United States) • Riverain Tech (United States) • 20/20 Gene Systems (United States) • Danaher Corporation (United States) • NeoGenomics (United States) • Eon Health (United States) • Siemens Healthineers AG (Germany‎) • Agilent Technologies, Inc., AstraZeneca (United Kingdom) • Insight Genetics (United Kingdom) • Inivata (United Kingdom) • Oncimmune (United Kingdom)

Market leaders are identified by primary and secondary research, and market revenue is calculated using primary and secondary research. The core study included in-depth interviews with key thought leaders and industry experts such as experienced front-line personnel, CEOs, and marketing executives. In-depth interviews with important thought leaders and industry experts, such as experienced front-line personnel, CEOs, and marketing executives, were conducted as part of primary research, while secondary research included a review of the major manufacturers' annual and financial reports. Secondary data is utilized to calculate percentage splits, market shares, growth rates, and global market breakdowns, which are then verified against primary data.

Regional Analysis:

Individual market influencing components and changes in market laws impacting current and future market trends are also covered in the lung Cancer Screening market analysis regional overview. Current and future trends are studied in order to evaluate the overall market potential and find profitable patterns in order to get a firmer footing. The geographical market evaluation is based on the current environment and anticipated trends.

COVID-19 Impact Analysis on lung Cancer Screening Market:

Due to a break in operations, end-user sectors where lung Cancer Screening are used suffered a drop in growth from January 2020 to May 2020 in a number of countries, including China, Italy, Germany, the United Kingdom, the United States, and Spain, France, and India. As a result, the revenues of enterprises in these industries fell significantly, as did the demand for lung Cancer Screening manufacturers, impacting the growth of the lung Cancer Screening market in 2020. Lockdowns and a surge in COVID-19 events globally have severely reduced end-user business demand for lung Cancer Screening.

Click Here to Get Sample Premium Report @ https://www.maximizemarketresearch.com/request-sample/166924

Key Questions Answered in the lung Cancer Screening Market Report are:

In 2021, which segment held the highest proportion of the lung Cancer Screening market?

What is the lung Cancer Screening market's competitive landscape?

What are the primary drivers assisting lung Cancer Screening market growth?

Which region has the most market share in the lung Cancer Screening market?

What will be the lung Cancer Screening market's CAGR throughout the projected period (2022-2027)?

About Us

Maximize Market Research provides B2B and B2C research on 12,500 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact Us:

MAXIMIZE MARKET RESEARCH PVT. LTD.

3rd Floor, Navale IT Park Phase 2,

Pune Banglore Highway,

Narhe, Pune, Maharashtra 411041, India.

Email: sales@maximizemarketresearch.com

Phone No.: +91 9607365656

Website: www.maximizemarketresearch.com

Other Report:

Warehouse Automation System Market https://www.maximizemarketresearch.com/market-report/warehouse-automation-system-market/167432/ Wet Chemicals Market https://www.maximizemarketresearch.com/market-report/wet-chemicals-market/167848/